A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)
capecitabine-base chemotherapy must be first-line chemotherapy.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent
The age is Above 18 years of age, \<70 years old
HR-positive \& HER2-negative
Metastatic breast cancer,incurable.
No prior chemotherapy for metastatic recurrence, if there is disease progression within 6 months after the end of the adjuvant chemotherapy, adjuvant chemotherapy as first-line treatment for metastatic lesions
Eastern Cooperative Oncology Group performance status (ECOG PS)=0\~1
The basic function of normal bone marrow
Functions of liver and kidney is normal
Expectation of life is more than 3 months
Agreed to take contraceptive measures during treatment
You may not be if
Previous toxicity was not recovered to 0-1 degrees
Central nervous system metastasis
Pregnancy or lactation
There are uncontrolled infection, myocardial infarction, thrombosis, etc.
There are uncontrolled chronic diseases such as diabetes, hypertension, peptic ulcer, chronic hepatitis, mental disease;
Researchers believe that is not suitable for the study
Patients with other malignant tumor history, except the healed skin basal cell carcinoma and carcinoma of uterine cervix;
Bilateral breast cancer
Clareo Health | A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)
